With 30 years’ experience in pharmaceutical portfolio management, Jenny has covered all aspects of a product’s lifecycle, including from early R&D to loss of exclusivity. In her current role as Global Leader of Pfizer’s Biosimilars business, Jenny leads global strategy, alliance management, M&A, market development and commercialization of biosimilars.

In her role she focuses on key federal and state policy issues impacting the franchises of Boehringer Ingelheim, with specific focus on biosimilars, pipeline products and reimbursement for the BI portfolio. Prior to her current role, Ms. Burich was at Otsuka Pharmaceutical Inc where she held a variety of roles in federal and state government affairs and reimbursement.Ms. Burich was also in reimbursement and policy consulting at Xcenda and Avalere Health. Ms. Burich received a master of science in public service management with an emphasis in public policy from DePaul University and a bachelor of arts in political science from the University of Northern Colorado.

Tiffany Fletcher, Head of Global Biosimilar Policy and Access, at Mylan, is responsible for the development and support of global policies to support biosimilars and increase patient access to high quality medicine. Tiffany has over twenty years of industry experience specializing in market access and reimbursement policy. An accomplished public policy leader, Tiffany has a talent for prepping the environment for complex product launches, including the successful development and execution of the government reimbursement strategy for the launch of the first biosimilar in the U.S. Prior to coming to Mylan, Tiffany spent five years at Sandoz Inc., A Novartis Division, leading in biosimilar and reimbursement policy development.

Over the 18 years’ working experience in China National Regulatory Authority and National Control Lab and two years’ scientist/technical officer working experience in WHO HQ through international recruit process. Accumulated Chemical Manufacture and Control for biological products at both national and international level mainly covers: 1)technical review and assessment for biological products; 2)quality control assay and reference substances research and development including WHO international measurement standards; 3)technical leadership and professional input to regulatory science and regulation convergence for both CFDA and WHO written standards in the area of biologics standardization

Amanda Hollis is a partner at Kirkland & Ellis. Amanda has been litigating patent cases for 15 years and has substantial experience representing patent owners and patent challengers in federal courts across the country, in the U.S. International Trade Commission, and before the Patent Trial and Appeal Board. Amanda’s practice has encompassed a broad range of technologies and subject matters, including biologics, pharmaceutical and chemical compositions, and medical devices among others. Amanda is lead counsel in a number of biosimilar related patent disputes.